Optimal Treatment for Patients with Oligometastatic Prostate Cancer Available to Purchase

https://doi.org/10.1016/j.euf.2017.10.014

2.

Kelly

SP

,

Anderson

WF

,

Rosenberg

PS

,

Cook

MB

.

Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States

.

Eur Urol Focus

.

2018 Jan

;

4

(

1

):

121

–

7

.

.

https://doi.org/10.1200/jco.1995.13.1.8

3.

Hellman

S

,

Weichselbaum

RR

.

Oligometastases

.

J Clin Oncol

.

1995 Jan

;

13

(

1

):

8

–

10

.

.

https://doi.org/10.1038/nrclinonc.2011.44

4.

Weichselbaum

RR

,

Hellman

S

.

Oligometastases revisited

.

Nat Rev Clin Oncol

.

2011 Jun

;

8

(

6

):

378

–

82

.

.

https://doi.org/10.1002/1097-0142(19880101)61:1%3c195::aid-cncr2820610133%3e3.0.co;2-y

5.

Soloway

MS

,

Hardeman

SW

,

Hickey

D

,

Raymond

J

,

Todd

B

,

Soloway

S

,

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

.

Cancer

.

1988 Jan 1

;

61

(

1

):

195

–

202

.

.

https://doi.org/10.1016/j.eururo.2015.07.004

6.

Ost

P

,

Jereczek-Fossa

BA

,

As

NV

,

Zilli

T

,

Muacevic

A

,

Olivier

K

,

Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis

.

Eur Urol

.

2016 Jan

;

69

(

1

):

9

–

12

.

.

https://doi.org/10.1016/j.eururo.2014.07.020

7.

Gandaglia

G

,

Karakiewicz

PI

,

Briganti

A

,

Passoni

NM

,

Schiffmann

J

,

Trudeau

V

,

Impact of the site of metastases on survival in patients with metastatic prostate cancer

.

Eur Urol

.

2015 Aug

;

68

(

2

):

325

–

34

.

.

https://doi.org/10.1002/pros.23645

8.

Francini

E

,

Gray

KP

,

Xie

W

,

Shaw

GK

,

Valença

L

,

Bernard

B

,

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

.

Prostate

.

2018 Sep

;

78

(

12

):

889

–

95

.

.

https://doi.org/10.1016/j.radonc.2016.07.021

9.

Sridharan

S

,

Steigler

A

,

Spry

NA

,

Joseph

D

,

Lamb

DS

,

Matthews

JH

,

Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial

.

Radiother Oncol

.

2016 Oct

;

121

(

1

):

98

–

102

.

.

https://doi.org/10.1016/j.juro.2012.06.046

10.

Tangen

CM

,

Hussain

MH

,

Higano

CS

,

Eisenberger

MA

,

Small

EJ

,

Wilding

G

,

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)

.

J Urol

.

2012 Oct

;

188

(

4

):

1164

–

9

.

.

https://doi.org/10.1056/NEJMoa1503747

11.

Sweeney

CJ

,

Chen

YH

,

Carducci

M

,

Liu

G

,

Jarrard

DF

,

Eisenberger

M

,

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer

.

N Engl J Med

.

2015 Aug 20

;

373

(

8

):

737

–

46

.

.

https://doi.org/10.1056/NEJMoa1704174

12.

Fizazi

K

,

Tran

N

,

Fein

L

,

Matsubara

N

,

Rodriguez-Antolin

A

,

Alekseev

BY

,

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

.

N Engl J Med

.

2017 Jul 27

;

377

(

4

):

352

–

60

.

.

https://doi.org/10.1200/JCO.2017.75.4853

13.

Ost

P

,

Reynders

D

,

Decaestecker

K

,

Fonteyne

V

,

Lumen

N

,

De Bruycker

A

,

Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial

.

J Clin Oncol

.

2018 Feb 10

;

36

(

5

):

446

–

53

.

.

https://doi.org/10.1001/jamaoncol.2020.0147

14.

Phillips

R

,

Shi

WY

,

Deek

M

,

Radwan

N

,

Lim

SJ

,

Antonarakis

ES

,

Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial

.

JAMA Oncol

.

2020 May 1

;

6

(

5

):

650

–

9

.

.

https://doi.org/10.1016/j.eururo.2018.06.004

15.

Siva

S

,

Bressel

M

,

Murphy

DG

,

Shaw

M

,

Chander

S

,

Violet

J

,

Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial

.

Eur Urol

.

2018 Oct

;

74

(

4

):

455

–

62

.

.

https://doi.org/10.1016/S0140-6736(18)32487-5

16.

Palma

DA

,

Olson

R

,

Harrow

S

,

Gaede

S

,

Louie

AV

,

Haasbeek

C

,

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

.

Lancet

.

2019 May 18

;

393

(

10185

):

2051

–

8

.

.

https://doi.org/10.1016/j.eururo.2018.10.041

17.

Ploussard

G

,

Gandaglia

G

,

Borgmann

H

,

de Visschere

P

,

Heidegger

I

,

Kretschmer

A

,

Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review

.

Eur Urol

.

2019 Oct

;

76

(

4

):

493

–

504

.

.

https://doi.org/10.1016/j.eururo.2013.11.012

18.

Culp

SH

,

Schellhammer

PF

,

Williams

MB

.

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study

.

Eur Urol

.

2014 Jun

;

65

(

6

):

1058

–

66

.

.

https://doi.org/10.1200/JCO.2016.67.4788

19.

Rusthoven

CG

,

Jones

BL

,

Flaig

TW

,

Crawford

ED

,

Koshy

M

,

Sher

DJ

,

Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer

.

J Clin Oncol

.

2016 Aug 20

;

34

(

24

):

2835

–

42

.

.

20.

Boeve

LMS

,

Hulshof

M

,

Vis

AN

,

Zwinderman

AH

,

Twisk

JWR

,

Witjes

WPJ

,

Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial

.

Eur Urol

.

2019 Mar

;

75

(

3

):

410

–

8

.

https://doi.org/10.1016/S0140-6736(18)32486-3

21.

Parker

CC

,

James

ND

,

Brawley

CD

,

Clarke

NW

,

Hoyle

AP

,

Ali

A

,

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

.

Lancet

.

2018 Dec 1

;

392

(

10162

):

2353

–

66

.

.

https://doi.org/10.1016/j.eururo.2019.02.003

22.

Burdett

S

,

Boevé

LM

,

Ingleby

FC

,

Fisher

DJ

,

Rydzewska

LH

,

Vale

CL

,

Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis

.

Eur Urol

.

2019 Jul

;

76

(

1

):

115

–

24

.

.

https://doi.org/10.1016/j.eururo.2020.01.012

23.

Gillessen

S

,

Attard

G

,

Beer

TM

,

Beltran

H

,

Bjartell

A

,

Bossi

A

,

Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019

.

Eur Urol

.

2020 Apr

;

77

(

4

):

508

–

47

.

.

https://doi.org/10.1016/j.juro.2014.09.089

24.

Heidenreich

A

,

Pfister

D

,

Porres

D

.

Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study

.

J Urol

.

2015 Mar

;

193

(

3

):

832

–

8

.

.

https://doi.org/10.1016/j.euf.2017.06.016

25.

Steuber

T

,

Berg

KD

,

Røder

MA

,

Brasso

K

,

Iversen

P

,

Huland

H

,

Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study

.

Eur Urol Focus

.

2017 Dec

;

3

(

6

):

646

–

9

.

.

https://doi.org/10.1016/j.eururo.2015.05.023

26.

Sooriakumaran

P

,

Karnes

J

,

Stief

C

,

Copsey

B

,

Montorsi

F

,

Hammerer

P

,

A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation

.

Eur Urol

.

2016 May

;

69

(

5

):

788

–

94

.

.

27.

Eiber

M

,

Maurer

T

,

Souvatzoglou

M

,

Beer

AJ

,

Ruffani

A

,

Haller

B

,

Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy

.

J Nucl Med

.

2015 May

;

56

(

5

):

668

–

74

.

28.

Nanni

C

,

Zanoni

L

,

Pultrone

C

,

Schiavina

R

,

Brunocilla

E

,

Lodi

F

,

(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial

.

Eur J Nucl Med Mol Imaging

.

2016 Aug

;

43

(

9

):

1601

–

10

.

29.

Schwenck

J

,

Rempp

H

,

Reischl

G

,

Kruck

S

,

Stenzl

A

,

Nikolaou

K

,

Comparison of ⁶⁸Ga-labelled PSMA-11 and ¹¹C-choline in the detection of prostate cancer metastases by PET/CT

.

Eur J Nucl Med Mol Imaging

.

2017 Jan

;

44

(

1

):

92

–

101

.

https://doi.org/10.1016/j.juro.2018.08.050

30.

Andriole

GL

,

Kostakoglu

L

,

Chau

A

,

Duan

F

,

Mahmood

U

,

Mankoff

DA

,

The impact of positron emission tomography with ¹⁸F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial

.

J Urol

.

2019 Feb

;

201

(

2

):

322

–

31

.

.

31.

Rousseau

E

,

Wilson

D

,

Lacroix-Poisson

F

,

Krauze

A

,

Chi

K

,

Gleave

M

,

A prospective study on ¹⁸F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer

.

J Nucl Med

.

2019 Nov

;

60

(

11

):

1587

–

93

.

32.

Eiber

M

,

Kroenke

M

,

Wurzer

A

,

Ulbrich

L

,

Jooss

L

,

Maurer

T

,

¹⁸F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy

.

J Nucl Med

.

2020 May

;

61

(

5

):

696

–

701

.

33.

Diao

W

,

Cao

Y

,

Su

D

,

Jia

Z

.

Impact of ⁶⁸ Gallium prostate-specific membrane antigen tracers on the management of patients with prostate cancer who experience biochemical recurrence

.

BJU Int

.

2021 Feb

;

127

(

2

):

153

–

63

.

https://doi.org/10.1002/pros.21259

34.

Fleischmann

A

,

Rocha

C

,

Schobinger

S

,

Seiler

R

,

Wiese

B

,

Thalmann

GN

.

Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases

.

Prostate

.

2011 Apr

;

71

(

5

):

453

–

60

.

.

https://doi.org/10.1002/cncr.20243

35.

Arora

R

,

Koch

MO

,

Eble

JN

,

Ulbright

TM

,

Li

L

,

Cheng

L

.

Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate

.

Cancer

.

2004 Jun 1

;

100

(

11

):

2362

–

6

.

.

https://doi.org/10.1038/sj.onc.1210843

36.

Clark

J

,

Attard

G

,

Jhavar

S

,

Flohr

P

,

Reid

A

,

De-Bono

J

,

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

.

Oncogene

.

2008 Mar 27

;

27

(

14

):

1993

–

2003

.

.

https://doi.org/10.1016/j.eururo.2012.03.050

37.

Lindberg

J

,

Klevebring

D

,

Liu

W

,

Neiman

M

,

Xu

J

,

Wiklund

P

,

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins

.

Eur Urol

.

2013 Feb

;

63

(

2

):

347

–

53

.

.

https://doi.org/10.1016/S1470-2045(10)70223-0

38.

Bolla

M

,

Van Tienhoven

G

,

Warde

P

,

Dubois

JB

,

Mirimanoff

RO

,

Storme

G

,

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

.

Lancet Oncol

.

2010 Nov

;

11

(

11

):

1066

–

73

.

.

https://doi.org/10.1200/JCO.2017.75.3657

39.

Kyriakopoulos

CE

,

Chen

YH

,

Carducci

MA

,

Liu

G

,

Jarrard

DF

,

Hahn

NM

,

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial

.

J Clin Oncol

.

2018 Apr 10

;

36

(

11

):

1080

–

7

.

.

https://doi.org/10.1016/j.eururo.2020.01.012

40.

Gillessen

S

,

Attard

G

,

Beer

TM

,

Beltran

H

,

Bjartell

A

,

Bossi

A

,

Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019

.

Eur Urol

.

2020 Apr

;

77

(

4

):

508

–

47

.

.

https://doi.org/10.1016/S1470-2045(19)30082-8

41.

Fizazi

K

,

Tran

N

,

Fein

L

,

Matsubara

N

,

Rodriguez-Antolin

A

,

Alekseev

BY

,

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

.

Lancet Oncol

.

2019 May

;

20

(

5

):

686

–

700

.

.

https://doi.org/10.1056/NEJMoa1702900

42.

James

ND

,

de Bono

JS

,

Spears

MR

,

Clarke

NW

,

Mason

MD

,

Dearnaley

DP

,

Abiraterone for prostate cancer not previously treated with hormone therapy

.

N Engl J Med

.

2017 Jul 27

;

377

(

4

):

338

–

51

.

.

https://doi.org/10.1093/annonc/mdz396

43.

Clarke

NW

,

Ali

A

,

Ingleby

FC

,

Hoyle

A

,

Amos

CL

,

Attard

G

,

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

.

Ann Oncol

.

2019 Dec 1

;

30

(

12

):

1992

–

2003

.

.

https://doi.org/10.1016/j.eururo.2019.08.006

44.

Hoyle

AP

,

Ali

A

,

James

ND

,

Cook

A

,

Parker

CC

,

de Bono

JS

,

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

.

Eur Urol

.

2019 Dec

;

76

(

6

):

719

–

28

.

.

45.

James

N

,

Rush

H

,

Clarke

N

,

Attard

G

,

Cook

A

,

Dearnaley

D

,

611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)

.

Ann Oncol

.

2020

;

31

:

S509

.

https://doi.org/10.1200/JCO.19.00799

46.

Armstrong

AJ

,

Szmulewitz

RZ

,

Petrylak

DP

,

Holzbeierlein

J

,

Villers

A

,

Azad

A

,

ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer

.

J Clin Oncol

.

2019 Nov 10

;

37

(

32

):

2974

–

86

.

.

https://doi.org/10.1056/NEJMoa1903307

47.

Chi

KN

,

Agarwal

N

,

Bjartell

A

,

Chung

BH

,

Pereira de Santana Gomes

AJ

,

Given

R

,

Apalutamide for metastatic, castration-sensitive prostate cancer

.

N Engl J Med

.

2019 Jul 4

;

381

(

1

):

13

–

24

.

.

48.

Aggarwal

RR

,

Eggener

SE

,

Chen

RC

,

Heller

G

,

Patnaik

A

,

Xiao

H

,

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an alliance foundation trial (AFT-19)

.

J Clin Oncol

.

2018

;

36

.